canagliflozin
Pharmaranks rates Canagliflozin 3.3/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Canagliflozin is a sodium-glucose cotransporter 2 inhibitor used to treat Type 2 Diabetes Mellitus.
Sodium-Glucose Cotransporter 2 Inhibitor · by Aurobindo Pharma Ltd
Generic of Invokana
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Canagliflozin
- Drug class
- Sodium-Glucose Cotransporter 2 Inhibitor
- Form
- Tablet
- Strength
- Canagliflozin 100MG · Canagliflozin 300MG
- Type
- Prescription (Rx)
- Brand or generic
- Generic
- May treat
- type 2 diabetes mellitus
- Manufacturer
- Aurobindo Pharma Ltd
- FDA application
- ANDA210386
- Availability
- Discontinued (per FDA)
Drug class
May treat (source: NIH RxClass)
See how Canagliflozin ranks — best-rated sodium-glucose cotransporter 2 inhibitor for:
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Canagliflozin treat?
- Canagliflozin (Canagliflozin) may be used to treat type 2 diabetes mellitus, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Canagliflozin rated?
- pharmaranks gives Canagliflozin a composite score of 3.3 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Canagliflozin?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Canagliflozin. To pay less, Canagliflozin is already a generic — usually the lowest-cost version — so the main levers are comparing cash prices between pharmacies and using a pharmacy discount-card service. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Canagliflozin?
- Canagliflozin is marketed by Aurobindo Pharma Ltd. You can see Aurobindo Pharma Ltd's full profile, rating, and other products on pharmaranks.
- Is Canagliflozin a brand-name or generic drug?
- Canagliflozin is a generic medication; its active ingredient is Canagliflozin. Generics contain the same active ingredient as the brand-name original and are usually lower cost.
- Is Canagliflozin available over the counter?
- No. Canagliflozin is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Canagliflozin come in?
- Canagliflozin is currently marketed as tablet, per the FDA's National Drug Code Directory.
- What class of drug is Canagliflozin?
- Canagliflozin is classified as sodium-glucose cotransporter 2 inhibitor, per the FDA's Established Pharmacologic Class.
- Is Canagliflozin FDA-registered?
- Canagliflozin is on record with the U.S. FDA under application number ANDA210386. You can verify this on its official FDA label.
- Has Canagliflozin been recalled by the FDA?
- Canagliflozin has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Canagliflozin safe?
- There's no single safe-or-not verdict. pharmaranks gives Canagliflozin a recall-safety score of 66/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about Canagliflozin
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3,342 reports naming Canagliflozin, and the FDA flagged 93% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- diabetic ketoacidosis374 reports
- acute kidney injury178 reports
- nausea173 reports
- asthma169 reports
- hyperglycaemia145 reports
- diarrhoea143 reports
- dyspnoea132 reports
- type 2 diabetes mellitus129 reports
Read these as a signal, not a rate. A report does not mean Canagliflozin caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Canagliflozin head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
canagliflozin
66/100